Conclusion: -
Pruritus is a common symptom in patients with PV resulting in significant morbidity. Amongst the many medications available for symptom control, ruxolitinib seems to be the most effective in managing PV-related pruritus. So, this case report sheds light on using ruxolitinib as the first-line treatment of refractory pruritus in PV patients.